Literature DB >> 14669834

Somatostatin and thyroid.

M C Zatelli1, E Roti, E C degli Uberti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14669834     DOI： 10.1007/BF03347362

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN： 0391-4097            Impact factor:   4.256


× No keyword cloud information.
  15 in total

1.  Current approaches and perspectives in the therapy of medullary thyroid carcinoma.

Authors:  G Vitale; M Caraglia; A Ciccarelli; G Lupoli; A Abbruzzese; P Tagliaferri; G Lupoli
Journal:  Cancer       Date:  2001-05-01       Impact factor: 6.860

2.  Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line.

Authors:  Maria C Zatelli; Federico Tagliati; Daniela Piccin; John E Taylor; Michael D Culler; Marta Bondanelli; Ettori C degli Uberti
Journal:  Biochem Biophys Res Commun       Date:  2002-10-04       Impact factor: 3.575

3.  Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

Authors:  E P Krenning; M de Jong; P P Kooij; W A Breeman; W H Bakker; W W de Herder; C H van Eijck; D J Kwekkeboom; F Jamar; S Pauwels; R Valkema
Journal:  Ann Oncol       Date:  1999       Impact factor: 32.976

4.  Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in nonmedullary thyroid cancer.

Authors:  R Görges; G Kahaly; J Müller-Brand; H Mäcke; H W Roser; A Bockisch
Journal:  Thyroid       Date:  2001-07       Impact factor: 6.568

5.  Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.

Authors:  M Papotti; U Kumar; M Volante; C Pecchioni; Y C Patel
Journal:  Clin Endocrinol (Oxf)       Date:  2001-05       Impact factor: 3.478

6.  Somatostatin reduces 3H-thymidine incorporation and c-myc, but not thyroglobulin ribonucleic acid levels in human thyroid follicular cells in vitro.

Authors:  E C degli Uberti; S Hanau; R Rossi; R Piva; A Margutti; G Trasforini; G Pansini; L del Senno
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

7.  Somatostatin receptor subtypes 2 and 5 differentially affect proliferation in vitro of the human medullary thyroid carcinoma cell line tt.

Authors:  M C Zatelli; F Tagliati; J E Taylor; R Rossi; M D Culler; E C degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2001-05       Impact factor: 5.958

8.  Inhibition of metabolic activity in papillary thyroid carcinoma by a somatostatin analogue.

Authors:  R J Robbins; R H Hill; W Wang; H H Macapinlac; S M Larson
Journal:  Thyroid       Date:  2000-02       Impact factor: 6.568

9.  Somatostatin analogs in the treatment of medullary thyroid carcinoma.

Authors:  J J Díez; P Iglesias
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

10.  Somatostatin, but not somatostatin receptor subtypes 2 and 5 selective agonists, inhibits calcitonin secretion and gene expression in the human medullary thyroid carcinoma cell line, TT.

Authors:  M C Zatelli; F Tagliati; J E Taylor; D Piccin; M D Culler; E C degli Uberti
Journal:  Horm Metab Res       Date:  2002-05       Impact factor: 2.936
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.